​​​​​

Photobiomodulation Equipment and Training - THOR Photomedicine

Select Region

Information contained on this page may not be appropriate for your region, please select your region from below. To navigate back to this region selector, please click "Region" in the footer.
Do More With A THOR
Lots of happy THOR customer testimonials
NovoTHOR Whole Body Light Pod

Laser Therapy & Sports Injuries

Quick, Simple and Safe

With the new "THOR 1W laser cluster" treatment times are only 20 seconds per treatment area. You don't have to be an expert on photobiology to give your patients the benefit. Just follow the simple treatment guidelines that come with every THOR laser.

If you want to broaden your knowledge come to one of the many one day THOR training seminars. You could even attend a conference and see first hand what the scientists are working on. Learn more about what you do now - see what you might be treating in the future.

THOR LLLT treatment of sports injuries

UK Soccer star Michael Owen gets LLLT treatment for a hamstring injury.

View more videos

Clinical Research



OUR CUSTOMERS INCLUDE:
Our customers include: Harvard Medical School, Massachusetts General Hospital, British Army, RAF, Royal Navy, Team GB, Manchester United, MIT, Harvard School of Public Health, Cedars Sinai, City of Hope, USUHS
THOR Customers

THOR Photomedicine Ltd is an ISO 13485:2016 certified medical device company.

The THOR LX2.3 Photobiomodulation system has a medical CE mark (EC certificate). It is indicated for oral mucositis, tendinopathies, joint pain, neck pain and back pain for marketing in the UK, EU and Australia.

The THOR LX2.3 Photobiomodulation system is also FDA Cleared for marketing in the United States for: Temporary increase in local blood circulation, temporary relief of minor muscle and joint aches, pains and stiffness and relaxation of muscles; for muscle spasms, and minor pain and stiffness associated with arthritis.

Excluding the THOR LED Helmet, THOR LX2 and NovoTHOR systems are manufactured under conditions fulfilling the quality system requirements of Annex II, excluding (4), of the directive 93/42/EEC as amended and satisfy the applicable international harmonised standards.

Positive systematic reviews published by:

The British Medical Journal (BMJ), The Lancet, the International Association for the Study of Pain (IASP), the World Health Organisation (WHO), the Multinational Association for Supportive Care in Cancer (MASCC), the European Society for Medical Oncology (ESMO)

Appropriate regulatory clearance or approvals include:

Quality certificates

​​​​​